Pharmacogenetic and Antidepressant Treatment in Elderly

Pharmacogenetic in the Therapeutic Strategy in Depressed Elderly

Status

Terminated

Phases

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT02856477

Acronym

Pharmacogeneti

Enrollment

Registered

2016-08-04

Start date

2007-11-30

Completion date

2016-04-30

Last updated

2016-08-05

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Depression

Brief summary

The study aims to assess the therapeutic benefits of the adaptation of the antidepressant dose to the metabolic capacity (cytochrome P450 2D6) of elderly depressed patients. Therapeutic benefits are evaluated through the enhancement of efficiency, decrease of the action time and the after effects.

Interventions

BIOLOGICALurine analysis

a sample of urine is collected during 8 hours.

Study design

Allocation

RANDOMIZED

Intervention model

PARALLEL

Masking

QUADRUPLE (Subject, Caregiver, Investigator, Outcomes Assessor)

Eligibility

Sex/Gender

ALL

Age

70 Years to No maximum

Healthy volunteers

Inclusion criteria

* current major depressive disorder * antidepressant treatment

Exclusion criteria

* dextromethorphan contra-indication * other psychiatric disorder * kidney failure * liver failure mini mental State Examination (MMSE)\<18

Design outcomes

Primary

Measure	Time frame	Description
patient remission	6 months	remission is defined by a Montgomery and asberg depression rating (MADRS) score\<10.

Countries

France

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026